NanoCor Therapeutics

NanoCor's Team NanoCor’s team is highly experienced in virology (AAV in particular), in the cardiovascular field and in the development of gene therapy based therapeutics. Dr. Richard Jude Samulski, the developer of the BNP™ technology, has almost 30 years of experience in rAAV and is the Director of the Gene Therapy Center at the University of North Carolina – Chapel Hill. Dr. Evangelia Kranias, the developer of the I-1 technology, is well known for her work in phospholambam and the biology of heart failure, and is the Distinguished Professor and Director of Cardiovascular Biology at the University of Cincinnati. Dr. Roger Hajjar is a leader in gene therapy techniques and model testing for cardiovascular diseases. Management Team Sheila A. Mikhail, J.D., M.B.A. Founder, Chief Executive Officer Board of Directors Sheila A. Mikhail, J.D., M.B.A. Founder, Chief Executive Officer Jude Samulski, Ph.D. Scientific Founder, Collaborator Gerald L. Klein, M.D. Board Member Founders Sheila A. Mikhail, J.D., M.B.A. Founder, Chief Executive Officer Gabor M. Rubanyi, M.D., Ph.D. Founder Scientific Advisory Board Jude Samulski, Ph.D. Scientific Founder, Collaborator Evangelia Kranias, Ph.D. Scientific Founder, Collaborator Roger Hajjar, MD, Ph.D. Scientific Founder, Collaborator William Abraham, M.D. Director of the Division of Cardiovascular Medicine at The Ohio State University Medical Center and a professor of Internal Medicine. Thomas DiSalvo, M.D. Chief Medical Director of the Vanderbilt Heart and Vascular Institute. Joshua Hare, M.D. Chief of the Division of Cardiology and director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine. David Kass, M.D. Professor of Medicine and Biomedical Engineering at Johns Hopkins University and a cardiology staff member at Johns Hopkins Hospital. Leslie Miller, M.D. Chief of the Integrated Divisions of Cardiology at the Georgetown University School of Medicine, Georgetown University Hospital and Washington Hospital Center. Sir Magdi Yacoub, M.D. British Heart Foundation Professor of Cardiothoracic Surgery at Imperial College of London and Founder and Director of Research at The Magdi Yacoub Institute, Heart Science Centre Harefield. Sir Yacoub has performed more transplants than any other surgeon in the world and has personally tended to Queen Elizabeth II. Collaborators UNC Chapel Hill Massachusetts General Hospital/Harvard University of Cincinnati Mount Sinai Medical Center
	NanoCor's Team
		Management Team Board of Directors Founders Advisory Board Collaborators . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
	Contact Us
		870 Martin Luther King Jr. Blvd. Chapel Hill, NC 27514 (919) 942-0252 smikhail@nanocorthx.com . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NanoCor Therapeutics, Inc. is engaged in the development of novel therapeutics for the treatment of various cardiovascular diseases at the molecular level. NanoCor’s lead therapeutic is Carfostin™, an intracellular protein therapeutic for the treatment of Chronic Heart Failure (CHF). Carfostin™ is comprised of the delivery of a therapeutic gene, protein Phosphatase-1 Inhibitor-1 (I-1) with the use of Biological NanoParticles (BNPs™) and the Self-Complementary Vector Technology. This novel approach, which represents an important adjunct to existing therapies, will provide a non-invasive treatment for these patients and advance the current standard of care.